Last kr5.00 SEK
Change Today -0.15 / -2.91%
Volume 1.6M
KAN On Other Exchanges
Symbol
Exchange
Stockholm
As of 12:00 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

kancera ab (KAN) Snapshot

Open
kr5.10
Previous Close
kr5.15
Day High
kr5.10
Day Low
kr4.68
52 Week High
01/20/14 - kr10.05
52 Week Low
12/18/13 - kr1.30
Market Cap
492.7M
Average Volume 10 Days
812.8K
EPS TTM
kr-0.22
Shares Outstanding
98.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KANCERA AB (KAN)

Related News

No related news articles were found.

kancera ab (KAN) Related Businessweek News

No Related Businessweek News Found

kancera ab (KAN) Details

Kancera AB, a biotechnology company, engages in the development and sale of drug candidates that cure or stop the progression of cancer. Its pharmaceutical development projects include PFKFB3 project, which targets the ability of solid tumors, such as breast, prostate, lung, and colon cancer to survive and resist chemotherapy and radiotherapy treatment; and ROR-1 project that aims to develop a targeted drug to treat chronic lymphatic leukemia. The company was founded in 2010 and is based in Solna, Sweden.

Founded in 2010

kancera ab (KAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kancera ab (KAN) Key Developments

Kancera AB Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Kancera AB reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of SEK 55,000 against SEK 241,000 a year ago. Operating loss was SEK 3,064,000 against SEK 2,736,000 a year ago. Loss after financial items was SEK 3,008,000 against SEK 2,738,000 a year ago. Net loss was SEK 3,008,000 against SEK 2,738,000 a year ago. Loss per share, before and after dilution was SEK 0.03 against SEK 0.08 a year ago. Cash outflow from operating activities was SEK 4,394,000 or SEK 0.04 per share against SEK 1,919,000 or SEK 0.06 per share a year ago. For the nine months, the company reported net sales of SEK 420,000 against SEK 459,000 a year ago. Operating loss was SEK 11,016,000 against SEK 8,321,000 a year ago. Loss after financial items was SEK 10,933,000 against SEK 5,320,000 a year ago. Net loss was SEK 10,933,000 against SEK 5,320,000 a year ago. Loss per share, before and after dilution was SEK 0.13 against SEK 0.16 a year ago. Cash outflow from operating activities was SEK 11,558,000 or SEK 0.16 per share against SEK 8,999,000 or SEK 0.09 per share a year ago. Investment in tangible assets was SEK 500,000.

Kancera AB Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Kancera AB reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net sales of SEK 153,000 against SEK 218,000 a year ago. Operating loss was SEK 3,803,000 against SEK 3,274,000 a year ago. Loss after financial items was SEK 3,752,000 against SEK 3,274,000 a year ago. Net loss was SEK 3,752,000 against SEK 3,274,000 a year ago. Loss per share, before and after dilution was SEK 0.05 against SEK 0.10 a year ago. Cash outflow from operating activities was SEK 3,991,000 against SEK 2,844,000 a year ago. For the six months, the company reported net sales of SEK 365,000 against SEK 218,000 a year ago. Operating loss was SEK 7,952,000 against SEK 5,585,000 a year ago. Loss after financial items was SEK 7,925,000 against SEK 2,584,000 a year ago. Net loss was SEK 7,925,000 against SEK 2,584,000 a year ago. Loss per share, before and after dilution was SEK 0.10 against SEK 0.08 a year ago. Cash outflow from operating activities was SEK 7,164,000 against SEK 5,080,000 a year ago. Investment in tangible assets was SEK 500,000 against SEK 2,000,000 a year ago.

Kancera AB Announces Earnings Results for the First Quarter Ended March 31, 2014

Kancera AB announced earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net sales of SEK 212,000. Operating loss was SEK 4,149,000 against SEK 2,311,000 a year ago. Financial loss was SEK 24,000 against financial income of SEK 3,001,000 a year ago. Loss after financial items was SEK 4,173,000 against income after financial items of SEK 690,000 a year ago. Net loss was SEK 4,173,000 against net income of SEK 690,000 a year ago. Loss per share, before and after dilution was SEK 0.06 against EPS of SEK 0.04 a year ago. Cash flow used in operating activities was SEK 3,173,000 against SEK 2,236,000 a year ago. Investment in tangible assets was SEK 500,000 against SEK 2,000 a year ago. Negative free cash flow available to investors was SEK 3,673,000 against SEK 4,236,000 a year ago. For the period, the company reported negative return on equity and negative return on capital employed. Cash flow per share was SEK 0.08 against SEK 0.01 a year ago. Kancera´s activities have mainly covered internal drug development projects alongside smaller consultancy projects which raised net sales during the period of SEK 0.2 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KAN:SS kr5.00 SEK -0.15

KAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KAN.
View Industry Companies
 

Industry Analysis

KAN

Industry Average

Valuation KAN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 267.8x
Price/Book 14.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 245.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KANCERA AB, please visit www.kancera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.